Advancing Survival in Relapsed/Refractory Multiple Myeloma

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Related Videos
Chandler H. Park, MD, an expert on renal cell carcinoma
Related Content